tobramycin
therapy
pulmonary
infection
patient
cystic
fibrosis
six
patient
exacerbation
chronic
pulmonary
infection
association
cystic
fibrosis
treated
intramuscular
tobramycin
mg
kg
day
divided
dos
eight
treatment
course
lasted
day
mean
serum
level
microg
ml
hour
microg
ml
hour
dose
tobramycin
mean
tobramycin
concentration
sputum
microg
ml
eighty
two
percent
pathogenic
bacterial
isolates
sputum
either
pseudomonas
sp
staphylococcus
aureus
ninety
seven
percent
pseudomonas
sp
percent
staphylococcus
aureus
inhibited
microg
tobramycin
per
ml
organism
isolated
therapy
observed
become
resistant
tobramycin
although
occasion
colonization
new
resistant
gram
negative
bacillus
occurred
course
therapy
patient
showed
clinical
improvement
elimination
bacterial
pathogen
sputum
rarely
achieved
necessary
produce
clinical
improvement
colonization
resistant
flora
uncommon
finding
tobramycin
side
effect
limited
local
discomfort
injection
site
nausea
vomiting
